Oral L-Dopa is the gold standard therapy for motor symptoms in people with Parkinson’s disease. Credit: sruilk / Shutterstock.com

Vistagen has received a Canadian Notice of Allowance for a patent related to the use of AV-101 in Parkinson’s disease (PD) patients.

The company received the Notice of Allowance from the Canadian Intellectual Property Office. 

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The treatment reduces the sudden uncontrolled movements, or dyskinesia, caused by using levodopa (L-Dopa), a PD medication.

AV-101 is an oral prodrug that acts on the N-methyl-D-aspartate receptor (NMDAR).

The patent in Canada is valid until 2034.

According to preclinical findings from the MPTP [1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine] non-human primate model of the disease, AV-101 substantially cut down L-Dopa-induced dyskinesia without impacting the degree, timing or length of L-Dopa’s benefits.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Behavioural scores using a dyskinesia scale and a Parkinsonian disability scale were utilised for measuring L-Dopa anti-Parkinsonian efficacy. 

No adverse events linked to AV-101 were observed.

In all clinical trials concluded so far, the drug was found to be well-tolerated without any serious adverse psychological side effects or other safety issues.

The company plans to advance AV-101 into the Phase IIA development stage for treating a range of neurological ailments involving the NMDAR.

Vistagen’s AV-101 had earlier received a patent from the US Patent and Trademark Office.

In spite of the dyskinesia risk, oral L-Dopa is the gold standard therapy for motor symptoms in people with PD.

In June 2023, the European Patent Office issued an intention to grant a patent for the company’s PH80 nasal spray to treat migraine.